Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $15.2 million.

  • ARS Pharmaceuticals' Gains from Investment Securities rose 200.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 64.52%. This contributed to the annual value of $15.2 million for FY2024, which is 31.91% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $15.2 million for FY2024, which was up 31.91% from $11.5 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Gains from Investment Securities peaked at $15.2 million during FY2024, and registered a low of $331,000 during FY2020.
  • Its 3-year average for Gains from Investment Securities is $12.9 million, with a median of $12.1 million in 2022.
  • Per our database at Business Quant, ARS Pharmaceuticals' Gains from Investment Securities soared by 1,358.81% in 2021 and then declined by 4.73% in 2023.
  • ARS Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $331,000 in 2020, then spiked by 1,358.81% to $4.8 million in 2021, then soared by 149.83% to $12.1 million in 2022, then decreased by 4.73% to $11.5 million in 2023, then soared by 31.91% to $15.2 million in 2024.